NIH Reporter #5R21AI181677-02

NIAID Grant for HIV/SIV Vaccine Research Targeting Viral Spike Apex Antibody Responses

This opportunity is a research grant from the National Institute of Allergy and Infectious Diseases (NIAID) for HIV/SIV vaccine development, in partnership with New York University School of Medicine. - Government Buyer: - National Institutes of Health (NIH) - National Institute of Allergy and Infectious Diseases (NIAID) - No OEMs or commercial vendors are specified, as this is a scientific research grant rather than a product or service procurement. - Products/Services Requested: - Research and development services focused on engineering a vaccine containing two spike-apical, antibody-targeted epitopes for HIV/SIV - Testing of the vaccine in a non-human primate model - Immunological analysis of antibody responses at the viral spike apex - Notable Requirements: - Emphasis on translational research to advance HIV vaccine design - Focus on antibody responses at the apex of the HIV/SIV viral spike - No specific product, equipment, or OEM requirements beyond the scientific research aims - Estimated funding for the project is $211,875 for the specified duration.

Description

This NIH grant opportunity funds research on HIV/SIV vaccine development focusing on antibody responses at the viral spike apex. The project aims to investigate whether antibody-targeted epitopes at the apex of the HIV/SIV viral spike can mediate protection from viral challenge by engineering a vaccine containing two key spike-apical epitopes. The study will test the vaccine in a non-human primate model to evaluate its efficacy in delaying viral acquisition. The research could lead to the design and translational development of a novel, efficacious HIV vaccine.

View original listing